MedTrace Logo

Durvalumab and Ablative Radiation in Small Cell Lung Cancer (DARES)

NCT05068232 · Status: RECRUITING · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 49

Last updated 2026-03-04

No results posted yet for this study

Summary

This this study is for individuals who have treatment-naïve extensive-stage small cell lung cancer (small cell lung cancer that wont respond to treatment). Doctors leading this study hope to learn if combining durvalumab, carboplatin and etoposide with hyofractionated ablative radiation therapy (radiation focused on certain parts of the body) will help treat your cancer and improve how long you can live with extensive-stage small cell cancer without it getting worse (progression-free survival). Your participation in this research will last about 48 months.

Durvalumab along with chemotherapy has been approved by the Food and Drug Administration (FDA) for the treatment of small cell lung cancer along with chemotherapy. This study is testing the addition of radiation to durvalumab and chemotherapy.

Conditions

  • Small-cell Lung Cancer
  • Extensive-stage Small-cell Lung Cancer
  • Lung Cancer

Interventions

RADIATION

Ablative Radiation

Ablative radiation therapy is a highly focused radiation treatment that gives an intense dose of radiation concentrated on a tumor or very specific area of the body, while limiting the radiation that affects surrounding organs.

DRUG

Durvalumab

Durvalumab is an immunotherapy drug -- a drug used to help boost your immune response to fight cancer.

DRUG

Etoposide

Etoposide is a chemotherapy drug approved for different kinds of cancer, including small cell lung cancer.

DRUG

Carboplatin

Carboplatin is a chemotherapy drug approved for different kinds of cancer, including small cell lung cancer.

Sponsors & Collaborators

  • University of Chicago

    lead OTHER

Principal Investigators

  • Christine Bestvina, MD · University of Chicago - Comprehensive Cancer Center

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-08-19
Primary Completion
2027-10-01
Completion
2027-10-01
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05068232 on ClinicalTrials.gov